Vimian Group AB Logo

Vimian Group AB

Global animal health company in pharma, medtech, diagnostics, and vet services.

VIMIAN | ST

Overview

Corporate Details

ISIN(s):
SE0015961982 (+2 more)
LEI:
549300OQ8R5TCAP0BS18
Country:
Sweden
Address:
Riddargatan 19, 114 57 Stockholm

Description

Vimian Group is a global animal health company that applies science and technology to improve animal well-being. The company operates across four main segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. Through its portfolio of businesses, Vimian develops, manufactures, and distributes a wide range of products and services, including pharmaceuticals, medical devices, diagnostic tools, and specialized veterinary care. Its growth strategy combines in-house research and development with the acquisition of innovative companies to expand its offerings for veterinary professionals, clinics, and laboratories.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-22 21:30
Vimian har beslutat om nyemission och återköp av ytterligare D-aktier, E1 2025-…
Swedish 110.0 KB
2025-12-22 21:30
Vimian has resolved to issue and repurchase additional class D shares, class E1…
English 109.8 KB
2025-11-28 17:30
Change in the number of shares and votes in Vimian
English 106.5 KB
2025-11-28 17:30
Förändring av antalet aktier och röster i Vimian
Swedish 106.7 KB
2025-11-24 07:15
Vimian Group AB (publ) appoints Alireza Tajbakhsh as CEO
English 111.4 KB
2025-11-24 07:15
Vimian Group AB (publ) utser Alireza Tajbakhsh till vd och koncernchef
Swedish 111.3 KB
2025-10-27 07:00
Vimian has resolved to issue and repurchase class D shares, class E1 2025 share…
English 101.0 KB
2025-10-27 07:00
Vimian har beslutat om nyemission och återköp av D-aktier, E1 2025-aktier, E2 2…
Swedish 101.1 KB
2025-10-22 07:45 Swedish 2.0 MB
2025-10-22 07:45 English 1.9 MB
2025-09-23 10:00
Nomination Committee for Vimian’s 2026 Annual General Meeting
English 97.6 KB
2025-09-23 10:00
Valberedning inför Vimians årsstämma 2026
Swedish 97.6 KB
2025-08-30 01:03
Superior Court of Delaware awards Vimian USD 40.2 million in indemnification di…
English 108.1 KB
2025-08-30 01:03
Superior Court i Delaware tilldömer Vimian 40,2 miljoner USD i skadeståndstvist
Swedish 108.5 KB
2025-07-31 17:30
Förändring av antalet aktier och röster i Vimian
Swedish 105.4 KB

Automate Your Workflow. Get a real-time feed of all Vimian Group AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vimian Group AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vimian Group AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-14 Sven Johan Magnus Göte Kjellberg Other Sell 425,000 19,167,500.00 SEK
2024-12-23 Sven Johan Magnus Göte Kjellberg Other Sell 25,000 1,026,000.00 SEK

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.